| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 152 | 2024 | 12033 | 5.140 |
Why?
|
| Thoracic Surgery | 25 | 2024 | 284 | 4.950 |
Why?
|
| Pneumonectomy | 57 | 2024 | 862 | 4.720 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 103 | 2024 | 5574 | 4.620 |
Why?
|
| Thoracic Surgical Procedures | 22 | 2024 | 259 | 4.320 |
Why?
|
| Education, Medical, Graduate | 18 | 2021 | 705 | 3.570 |
Why?
|
| Esophageal Neoplasms | 67 | 2024 | 3240 | 2.870 |
Why?
|
| Internship and Residency | 21 | 2023 | 1452 | 2.560 |
Why?
|
| Esophagectomy | 40 | 2024 | 946 | 2.520 |
Why?
|
| Metastasectomy | 9 | 2023 | 209 | 1.730 |
Why?
|
| Postoperative Complications | 42 | 2024 | 5681 | 1.490 |
Why?
|
| Thoracic Neoplasms | 8 | 2018 | 363 | 1.440 |
Why?
|
| Adenocarcinoma | 50 | 2024 | 7914 | 1.350 |
Why?
|
| Cardiac Surgical Procedures | 8 | 2020 | 1158 | 1.300 |
Why?
|
| Neoplasm Staging | 82 | 2023 | 14012 | 1.110 |
Why?
|
| Neoplasm Recurrence, Local | 39 | 2024 | 10400 | 1.110 |
Why?
|
| Neoadjuvant Therapy | 42 | 2024 | 5231 | 1.100 |
Why?
|
| Humans | 322 | 2024 | 270740 | 1.100 |
Why?
|
| Learning | 4 | 2019 | 431 | 1.070 |
Why?
|
| Sarcoma | 13 | 2018 | 1839 | 1.050 |
Why?
|
| Retrospective Studies | 134 | 2024 | 39890 | 1.020 |
Why?
|
| Internet | 4 | 2019 | 690 | 0.950 |
Why?
|
| Pleural Neoplasms | 14 | 2021 | 485 | 0.950 |
Why?
|
| Heart Neoplasms | 8 | 2012 | 209 | 0.940 |
Why?
|
| Aged | 169 | 2024 | 73333 | 0.930 |
Why?
|
| Male | 212 | 2024 | 128315 | 0.920 |
Why?
|
| Chest Tubes | 2 | 2024 | 119 | 0.910 |
Why?
|
| Middle Aged | 182 | 2024 | 90352 | 0.900 |
Why?
|
| Radiosurgery | 6 | 2020 | 1383 | 0.860 |
Why?
|
| Specialties, Surgical | 3 | 2021 | 135 | 0.850 |
Why?
|
| Female | 208 | 2024 | 148940 | 0.850 |
Why?
|
| Thoracic Surgery, Video-Assisted | 11 | 2022 | 211 | 0.830 |
Why?
|
| Career Choice | 5 | 2020 | 210 | 0.830 |
Why?
|
| Thoracotomy | 7 | 2022 | 218 | 0.830 |
Why?
|
| Curriculum | 12 | 2021 | 919 | 0.820 |
Why?
|
| Clinical Competence | 9 | 2023 | 1325 | 0.810 |
Why?
|
| Thoracic Wall | 5 | 2018 | 188 | 0.790 |
Why?
|
| Checklist | 3 | 2020 | 125 | 0.760 |
Why?
|
| Educational Measurement | 7 | 2023 | 397 | 0.750 |
Why?
|
| Surgeons | 4 | 2021 | 491 | 0.740 |
Why?
|
| Survival Rate | 58 | 2024 | 12541 | 0.720 |
Why?
|
| Sternum | 3 | 2018 | 96 | 0.710 |
Why?
|
| Formative Feedback | 2 | 2019 | 33 | 0.700 |
Why?
|
| Carcinoma, Squamous Cell | 28 | 2021 | 5593 | 0.700 |
Why?
|
| Computer-Assisted Instruction | 2 | 2019 | 85 | 0.670 |
Why?
|
| Teaching | 3 | 2016 | 250 | 0.660 |
Why?
|
| Mesothelioma | 13 | 2021 | 558 | 0.660 |
Why?
|
| Treatment Outcome | 77 | 2024 | 33737 | 0.650 |
Why?
|
| Colorectal Neoplasms | 10 | 2023 | 3707 | 0.620 |
Why?
|
| Program Evaluation | 2 | 2020 | 603 | 0.600 |
Why?
|
| Prognosis | 55 | 2024 | 22505 | 0.600 |
Why?
|
| Editorial Policies | 1 | 2018 | 78 | 0.600 |
Why?
|
| Cardiology | 3 | 2018 | 511 | 0.590 |
Why?
|
| Adult | 116 | 2024 | 82040 | 0.580 |
Why?
|
| Aged, 80 and over | 68 | 2023 | 30998 | 0.570 |
Why?
|
| Patient Discharge | 5 | 2022 | 698 | 0.550 |
Why?
|
| Follow-Up Studies | 45 | 2024 | 15218 | 0.550 |
Why?
|
| Esophagogastric Junction | 10 | 2023 | 557 | 0.550 |
Why?
|
| Certification | 2 | 2019 | 107 | 0.540 |
Why?
|
| Social Media | 1 | 2020 | 208 | 0.530 |
Why?
|
| Postoperative Care | 6 | 2021 | 728 | 0.520 |
Why?
|
| Anterior Temporal Lobectomy | 1 | 2015 | 34 | 0.500 |
Why?
|
| Periodicals as Topic | 2 | 2018 | 317 | 0.500 |
Why?
|
| Pain, Postoperative | 6 | 2021 | 662 | 0.490 |
Why?
|
| Pleural Cavity | 1 | 2014 | 26 | 0.490 |
Why?
|
| Lymph Nodes | 10 | 2021 | 3077 | 0.490 |
Why?
|
| Fluorodeoxyglucose F18 | 8 | 2024 | 1260 | 0.480 |
Why?
|
| Bone Neoplasms | 6 | 2018 | 2665 | 0.470 |
Why?
|
| Carcinoma, Small Cell | 3 | 2015 | 427 | 0.450 |
Why?
|
| Quality of Health Care | 1 | 2018 | 618 | 0.450 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2022 | 1032 | 0.450 |
Why?
|
| Coronary Artery Bypass | 1 | 2017 | 530 | 0.450 |
Why?
|
| Osteotomy | 1 | 2014 | 105 | 0.440 |
Why?
|
| Multivariate Analysis | 21 | 2023 | 4328 | 0.440 |
Why?
|
| Pulmonary Surgical Procedures | 3 | 2021 | 25 | 0.430 |
Why?
|
| Lung | 16 | 2024 | 3298 | 0.430 |
Why?
|
| Coronary Vessels | 1 | 2017 | 626 | 0.430 |
Why?
|
| Prospective Studies | 24 | 2024 | 13414 | 0.430 |
Why?
|
| Length of Stay | 7 | 2024 | 2007 | 0.430 |
Why?
|
| Quality Improvement | 1 | 2020 | 914 | 0.420 |
Why?
|
| Education, Distance | 1 | 2014 | 100 | 0.420 |
Why?
|
| Survival Analysis | 33 | 2021 | 9292 | 0.420 |
Why?
|
| Consensus | 1 | 2017 | 1106 | 0.420 |
Why?
|
| Combined Modality Therapy | 41 | 2024 | 9039 | 0.410 |
Why?
|
| Disease-Free Survival | 29 | 2021 | 10265 | 0.410 |
Why?
|
| Self Report | 3 | 2023 | 796 | 0.410 |
Why?
|
| Time Factors | 33 | 2023 | 13006 | 0.400 |
Why?
|
| Dexmedetomidine | 3 | 2021 | 87 | 0.400 |
Why?
|
| Chemoradiotherapy | 10 | 2021 | 2027 | 0.400 |
Why?
|
| Neutrophils | 7 | 2020 | 873 | 0.390 |
Why?
|
| Pain Management | 3 | 2021 | 712 | 0.380 |
Why?
|
| Biomedical Research | 1 | 2018 | 801 | 0.380 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2024 | 180 | 0.370 |
Why?
|
| Databases, Factual | 15 | 2023 | 2250 | 0.370 |
Why?
|
| Texas | 24 | 2019 | 6449 | 0.370 |
Why?
|
| Risk Factors | 32 | 2023 | 17888 | 0.360 |
Why?
|
| Risk Assessment | 14 | 2020 | 6764 | 0.360 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 884 | 0.360 |
Why?
|
| Chemoradiotherapy, Adjuvant | 6 | 2021 | 562 | 0.360 |
Why?
|
| Esophagus | 3 | 2012 | 563 | 0.350 |
Why?
|
| Reminder Systems | 1 | 2011 | 70 | 0.350 |
Why?
|
| Pneumonia | 7 | 2023 | 796 | 0.350 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2022 | 2386 | 0.350 |
Why?
|
| Behavior | 2 | 2021 | 100 | 0.350 |
Why?
|
| Education, Medical | 1 | 2014 | 344 | 0.340 |
Why?
|
| Kaplan-Meier Estimate | 21 | 2024 | 6256 | 0.340 |
Why?
|
| Proportional Hazards Models | 17 | 2024 | 5101 | 0.340 |
Why?
|
| Precancerous Conditions | 3 | 2021 | 1059 | 0.340 |
Why?
|
| United States | 23 | 2024 | 15861 | 0.330 |
Why?
|
| Positron-Emission Tomography | 9 | 2024 | 2197 | 0.330 |
Why?
|
| Operating Rooms | 2 | 2021 | 128 | 0.330 |
Why?
|
| Anastomotic Leak | 2 | 2024 | 83 | 0.320 |
Why?
|
| Induction Chemotherapy | 4 | 2018 | 670 | 0.320 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2023 | 417 | 0.310 |
Why?
|
| Stomach | 2 | 2012 | 402 | 0.310 |
Why?
|
| Propensity Score | 8 | 2021 | 772 | 0.310 |
Why?
|
| B7-H1 Antigen | 6 | 2023 | 1089 | 0.310 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2011 | 205 | 0.310 |
Why?
|
| Aprotinin | 2 | 2007 | 30 | 0.310 |
Why?
|
| Biomarkers, Tumor | 10 | 2023 | 10708 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 25 | 2023 | 16689 | 0.300 |
Why?
|
| Chemotherapy, Adjuvant | 17 | 2021 | 4000 | 0.300 |
Why?
|
| Analgesics, Opioid | 4 | 2021 | 1468 | 0.300 |
Why?
|
| Kidney Neoplasms | 3 | 2022 | 3108 | 0.300 |
Why?
|
| Tomography, X-Ray Computed | 16 | 2024 | 7783 | 0.300 |
Why?
|
| Circulating Tumor DNA | 2 | 2023 | 274 | 0.290 |
Why?
|
| Cohort Studies | 23 | 2022 | 9470 | 0.290 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 1302 | 0.290 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2019 | 117 | 0.280 |
Why?
|
| Esophagoscopy | 4 | 2021 | 310 | 0.280 |
Why?
|
| Attitude of Health Personnel | 4 | 2021 | 901 | 0.280 |
Why?
|
| Endothelium, Vascular | 5 | 1995 | 879 | 0.280 |
Why?
|
| Societies, Medical | 2 | 2012 | 1320 | 0.270 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2007 | 182 | 0.270 |
Why?
|
| Stomach Neoplasms | 6 | 2023 | 2331 | 0.270 |
Why?
|
| Models, Educational | 2 | 2019 | 93 | 0.270 |
Why?
|
| Osteosarcoma | 3 | 2016 | 950 | 0.260 |
Why?
|
| Radiopharmaceuticals | 7 | 2024 | 1341 | 0.260 |
Why?
|
| Lymphatic Metastasis | 13 | 2021 | 4963 | 0.260 |
Why?
|
| Cell Adhesion Molecules | 7 | 1995 | 572 | 0.260 |
Why?
|
| Dyspnea | 3 | 2011 | 420 | 0.260 |
Why?
|
| Anastomosis, Surgical | 5 | 2017 | 370 | 0.250 |
Why?
|
| Smoking Cessation | 2 | 2021 | 776 | 0.250 |
Why?
|
| Salvage Therapy | 8 | 2021 | 2123 | 0.250 |
Why?
|
| Preoperative Care | 12 | 2019 | 1567 | 0.250 |
Why?
|
| Sexism | 2 | 2023 | 57 | 0.250 |
Why?
|
| Positron Emission Tomography Computed Tomography | 4 | 2024 | 880 | 0.250 |
Why?
|
| Radiotherapy, Adjuvant | 13 | 2018 | 2271 | 0.250 |
Why?
|
| Ipilimumab | 4 | 2023 | 764 | 0.240 |
Why?
|
| Robotic Surgical Procedures | 3 | 2021 | 533 | 0.240 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 2004 | 59 | 0.240 |
Why?
|
| Surveys and Questionnaires | 11 | 2023 | 5923 | 0.240 |
Why?
|
| Patient Selection | 6 | 2021 | 2025 | 0.240 |
Why?
|
| Incidence | 12 | 2023 | 5824 | 0.230 |
Why?
|
| Lung Diseases | 3 | 2021 | 755 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 12 | 2019 | 4048 | 0.230 |
Why?
|
| Intergenerational Relations | 2 | 2021 | 15 | 0.230 |
Why?
|
| Chylothorax | 1 | 2024 | 43 | 0.230 |
Why?
|
| Telemedicine | 1 | 2011 | 552 | 0.230 |
Why?
|
| Tumor Microenvironment | 8 | 2022 | 3035 | 0.230 |
Why?
|
| Proton Therapy | 3 | 2020 | 1637 | 0.220 |
Why?
|
| ErbB Receptors | 8 | 2023 | 2375 | 0.220 |
Why?
|
| Chondrosarcoma | 2 | 2016 | 213 | 0.220 |
Why?
|
| Acrylamides | 1 | 2023 | 68 | 0.220 |
Why?
|
| Ataxia Telangiectasia | 1 | 2023 | 62 | 0.220 |
Why?
|
| Endosonography | 5 | 2009 | 551 | 0.220 |
Why?
|
| Tracheal Neoplasms | 1 | 2003 | 44 | 0.220 |
Why?
|
| Octreotide | 1 | 2024 | 131 | 0.220 |
Why?
|
| Gastrointestinal Agents | 1 | 2024 | 118 | 0.220 |
Why?
|
| Young Adult | 19 | 2020 | 22251 | 0.220 |
Why?
|
| Hydrothorax | 1 | 2003 | 18 | 0.210 |
Why?
|
| Antineoplastic Agents | 8 | 2023 | 14617 | 0.210 |
Why?
|
| Cisplatin | 12 | 2020 | 2497 | 0.210 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 495 | 0.210 |
Why?
|
| Mutation | 12 | 2023 | 15912 | 0.210 |
Why?
|
| Medical Staff, Hospital | 2 | 2021 | 121 | 0.210 |
Why?
|
| Heart Transplantation | 4 | 2008 | 897 | 0.210 |
Why?
|
| Atrial Fibrillation | 2 | 2014 | 730 | 0.210 |
Why?
|
| Predictive Value of Tests | 12 | 2020 | 4960 | 0.200 |
Why?
|
| Thyroid Diseases | 1 | 2022 | 85 | 0.200 |
Why?
|
| Faculty, Medical | 2 | 2017 | 313 | 0.200 |
Why?
|
| Cause of Death | 3 | 2015 | 789 | 0.200 |
Why?
|
| Travel | 2 | 2023 | 203 | 0.200 |
Why?
|
| Pleura | 2 | 2021 | 130 | 0.190 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 6 | 2023 | 1402 | 0.190 |
Why?
|
| Smoking | 4 | 2021 | 2555 | 0.190 |
Why?
|
| North America | 3 | 2018 | 338 | 0.190 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2022 | 76 | 0.190 |
Why?
|
| Surgical Oncology | 1 | 2024 | 211 | 0.190 |
Why?
|
| General Surgery | 2 | 2018 | 333 | 0.190 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2021 | 30 | 0.190 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2023 | 216 | 0.190 |
Why?
|
| CD3 Complex | 1 | 2022 | 320 | 0.180 |
Why?
|
| Perioperative Care | 3 | 2019 | 447 | 0.180 |
Why?
|
| Thyroid Neoplasms | 2 | 2022 | 1894 | 0.180 |
Why?
|
| Nursing Staff, Hospital | 1 | 2021 | 74 | 0.180 |
Why?
|
| Neoplasm, Residual | 5 | 2018 | 1754 | 0.180 |
Why?
|
| 5'-Nucleotidase | 1 | 2021 | 63 | 0.180 |
Why?
|
| Indoles | 2 | 2023 | 1028 | 0.180 |
Why?
|
| Telecommunications | 1 | 2020 | 27 | 0.180 |
Why?
|
| Melanoma | 3 | 2023 | 5595 | 0.180 |
Why?
|
| Healthcare Disparities | 2 | 2023 | 657 | 0.180 |
Why?
|
| Camptothecin | 5 | 2014 | 540 | 0.180 |
Why?
|
| Barrett Esophagus | 2 | 2021 | 559 | 0.180 |
Why?
|
| Carcinoma | 4 | 2020 | 2610 | 0.180 |
Why?
|
| Occupational Stress | 1 | 2020 | 13 | 0.180 |
Why?
|
| Patient Readmission | 3 | 2021 | 572 | 0.180 |
Why?
|
| Acute Kidney Injury | 2 | 2020 | 761 | 0.180 |
Why?
|
| Carcinogenesis | 3 | 2021 | 1033 | 0.180 |
Why?
|
| Adolescent | 19 | 2023 | 32767 | 0.170 |
Why?
|
| Bupivacaine | 1 | 2020 | 73 | 0.170 |
Why?
|
| Intercellular Adhesion Molecule-1 | 6 | 1995 | 227 | 0.170 |
Why?
|
| Surgical Flaps | 3 | 2012 | 894 | 0.170 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2002 | 391 | 0.170 |
Why?
|
| Occupational Health | 1 | 2020 | 90 | 0.170 |
Why?
|
| Polytetrafluoroethylene | 2 | 2017 | 109 | 0.170 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 282 | 0.170 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2021 | 1121 | 0.170 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 135 | 0.170 |
Why?
|
| Specialty Boards | 1 | 2019 | 40 | 0.170 |
Why?
|
| Telephone | 3 | 2021 | 160 | 0.170 |
Why?
|
| Logistic Models | 9 | 2019 | 3444 | 0.170 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2020 | 743 | 0.160 |
Why?
|
| Cancer Care Facilities | 6 | 2019 | 907 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2015 | 1584 | 0.160 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 112 | 0.160 |
Why?
|
| Analysis of Variance | 11 | 2018 | 2315 | 0.160 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2020 | 2178 | 0.160 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2022 | 714 | 0.160 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 153 | 0.160 |
Why?
|
| Disease Progression | 8 | 2021 | 6867 | 0.160 |
Why?
|
| Microwaves | 1 | 2018 | 33 | 0.160 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 143 | 0.160 |
Why?
|
| Body Mass Index | 4 | 2017 | 2232 | 0.160 |
Why?
|
| Recovery of Function | 3 | 2018 | 681 | 0.160 |
Why?
|
| Congresses as Topic | 1 | 2020 | 299 | 0.160 |
Why?
|
| Radiography, Thoracic | 4 | 2017 | 477 | 0.160 |
Why?
|
| Carboplatin | 4 | 2017 | 880 | 0.150 |
Why?
|
| eIF-2 Kinase | 1 | 2019 | 166 | 0.150 |
Why?
|
| Bronchial Fistula | 1 | 2018 | 37 | 0.150 |
Why?
|
| Surgical Mesh | 2 | 2018 | 212 | 0.150 |
Why?
|
| Jejunum | 2 | 2012 | 228 | 0.150 |
Why?
|
| Interleukin-2 | 1 | 2022 | 889 | 0.150 |
Why?
|
| Cutaneous Fistula | 1 | 2018 | 45 | 0.150 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 379 | 0.150 |
Why?
|
| Gastrectomy | 4 | 2023 | 476 | 0.150 |
Why?
|
| Models, Anatomic | 2 | 2016 | 146 | 0.150 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 917 | 0.150 |
Why?
|
| Sex Factors | 6 | 2020 | 2184 | 0.150 |
Why?
|
| Paclitaxel | 8 | 2017 | 2101 | 0.150 |
Why?
|
| Self Concept | 1 | 2019 | 198 | 0.150 |
Why?
|
| Career Mobility | 1 | 2018 | 89 | 0.150 |
Why?
|
| Natural Language Processing | 1 | 2018 | 112 | 0.150 |
Why?
|
| Rad51 Recombinase | 1 | 2018 | 125 | 0.150 |
Why?
|
| Ketamine | 1 | 2021 | 238 | 0.150 |
Why?
|
| Ticlopidine | 1 | 2017 | 49 | 0.150 |
Why?
|
| Opioid-Related Disorders | 2 | 2019 | 419 | 0.150 |
Why?
|
| Heparin | 1 | 2019 | 342 | 0.150 |
Why?
|
| Hospital Mortality | 3 | 2018 | 1234 | 0.150 |
Why?
|
| Proteolysis | 1 | 2019 | 380 | 0.150 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2022 | 481 | 0.140 |
Why?
|
| Patient Care Team | 2 | 2021 | 823 | 0.140 |
Why?
|
| Critical Care | 1 | 2023 | 796 | 0.140 |
Why?
|
| Respiratory Function Tests | 1 | 2018 | 354 | 0.140 |
Why?
|
| Teacher Training | 1 | 2016 | 7 | 0.140 |
Why?
|
| Lysosomes | 1 | 2019 | 345 | 0.140 |
Why?
|
| Blood Component Removal | 1 | 2017 | 119 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2021 | 672 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2008 | 324 | 0.140 |
Why?
|
| Margins of Excision | 1 | 2018 | 315 | 0.140 |
Why?
|
| Thoracoplasty | 1 | 2016 | 17 | 0.140 |
Why?
|
| Intraoperative Care | 2 | 2015 | 274 | 0.140 |
Why?
|
| Radiotherapy, Conformal | 4 | 2007 | 898 | 0.130 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2017 | 398 | 0.130 |
Why?
|
| Delphi Technique | 1 | 2017 | 275 | 0.130 |
Why?
|
| Peritoneal Neoplasms | 1 | 2023 | 859 | 0.130 |
Why?
|
| Carbon Dioxide | 1 | 2017 | 328 | 0.130 |
Why?
|
| Neoplasms | 5 | 2023 | 15927 | 0.130 |
Why?
|
| Prosthesis-Related Infections | 1 | 2018 | 230 | 0.130 |
Why?
|
| Information Dissemination | 1 | 2018 | 268 | 0.130 |
Why?
|
| Competitive Behavior | 1 | 2015 | 16 | 0.130 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2019 | 557 | 0.130 |
Why?
|
| Mediastinum | 3 | 2019 | 276 | 0.130 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2015 | 19 | 0.130 |
Why?
|
| Acellular Dermis | 1 | 2017 | 101 | 0.130 |
Why?
|
| Diaphragm | 1 | 2017 | 187 | 0.130 |
Why?
|
| Faculty | 1 | 2016 | 132 | 0.130 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2015 | 38 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 9042 | 0.120 |
Why?
|
| Hemostasis | 2 | 2007 | 98 | 0.120 |
Why?
|
| Fluorouracil | 10 | 2014 | 1990 | 0.120 |
Why?
|
| SEER Program | 1 | 2019 | 1047 | 0.120 |
Why?
|
| Taxoids | 2 | 2017 | 1015 | 0.120 |
Why?
|
| Transcriptome | 2 | 2021 | 1963 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2019 | 411 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2019 | 727 | 0.120 |
Why?
|
| Betacoronavirus | 1 | 2020 | 514 | 0.120 |
Why?
|
| Vascular Neoplasms | 2 | 2009 | 112 | 0.120 |
Why?
|
| Thymus Neoplasms | 1 | 2020 | 416 | 0.120 |
Why?
|
| Physicians | 1 | 2023 | 854 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 327 | 0.120 |
Why?
|
| Evolution, Molecular | 1 | 2019 | 867 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 6177 | 0.120 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 929 | 0.120 |
Why?
|
| Complement System Proteins | 1 | 1995 | 135 | 0.120 |
Why?
|
| Nephrectomy | 2 | 2022 | 798 | 0.120 |
Why?
|
| Macrophage-1 Antigen | 2 | 1995 | 55 | 0.120 |
Why?
|
| Treatment Failure | 6 | 2020 | 1430 | 0.120 |
Why?
|
| Neoplasm Metastasis | 6 | 2021 | 5315 | 0.120 |
Why?
|
| Fluorocarbons | 1 | 2005 | 64 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2019 | 775 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 206 | 0.110 |
Why?
|
| Forecasting | 2 | 2014 | 702 | 0.110 |
Why?
|
| DNA Methylation | 2 | 2021 | 2765 | 0.110 |
Why?
|
| Respiration, Artificial | 1 | 2017 | 585 | 0.110 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1993 | 144 | 0.110 |
Why?
|
| Algorithms | 2 | 2023 | 3891 | 0.110 |
Why?
|
| Health Personnel | 1 | 2019 | 652 | 0.110 |
Why?
|
| Complement C3b | 1 | 1993 | 9 | 0.110 |
Why?
|
| Thrombosis | 2 | 2014 | 743 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 602 | 0.110 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2005 | 289 | 0.110 |
Why?
|
| Albumins | 1 | 2005 | 262 | 0.110 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 2 | 2023 | 118 | 0.110 |
Why?
|
| Mice, SCID | 4 | 2019 | 1826 | 0.110 |
Why?
|
| Reoperation | 5 | 2019 | 1392 | 0.110 |
Why?
|
| Personnel Selection | 1 | 2014 | 89 | 0.110 |
Why?
|
| Pilot Projects | 3 | 2017 | 2828 | 0.100 |
Why?
|
| Spinal Neoplasms | 3 | 2009 | 670 | 0.100 |
Why?
|
| Superoxides | 1 | 1993 | 218 | 0.100 |
Why?
|
| Esophagoplasty | 1 | 2012 | 28 | 0.100 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2013 | 124 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 831 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2021 | 1655 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 625 | 0.100 |
Why?
|
| Remission Induction | 7 | 2017 | 3656 | 0.100 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 4492 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 700 | 0.100 |
Why?
|
| Chi-Square Distribution | 5 | 2017 | 1312 | 0.100 |
Why?
|
| Diffusion of Innovation | 1 | 2013 | 141 | 0.100 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2012 | 30 | 0.100 |
Why?
|
| Perception | 2 | 2012 | 349 | 0.100 |
Why?
|
| DNA-Cytosine Methylases | 1 | 2012 | 15 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2014 | 822 | 0.100 |
Why?
|
| Job Satisfaction | 2 | 2012 | 122 | 0.100 |
Why?
|
| Feasibility Studies | 5 | 2021 | 2353 | 0.100 |
Why?
|
| Heart Atria | 2 | 2012 | 354 | 0.100 |
Why?
|
| Pulmonary Artery | 2 | 2009 | 521 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 1958 | 0.100 |
Why?
|
| Omentum | 1 | 2012 | 108 | 0.100 |
Why?
|
| Treatment Refusal | 1 | 2012 | 128 | 0.100 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 517 | 0.100 |
Why?
|
| Thrombectomy | 2 | 2022 | 167 | 0.100 |
Why?
|
| Vena Cava, Inferior | 2 | 2022 | 194 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2013 | 419 | 0.100 |
Why?
|
| Acute Lung Injury | 1 | 2012 | 92 | 0.100 |
Why?
|
| Telomere | 1 | 2015 | 550 | 0.100 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2023 | 256 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 3 | 2006 | 1388 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1840 | 0.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 1097 | 0.090 |
Why?
|
| Leadership | 1 | 2014 | 271 | 0.090 |
Why?
|
| Cell Adhesion | 2 | 1994 | 1028 | 0.090 |
Why?
|
| Antigen-Antibody Complex | 4 | 1995 | 122 | 0.090 |
Why?
|
| DNA | 3 | 2012 | 3050 | 0.090 |
Why?
|
| Leukocytes | 1 | 1993 | 421 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 909 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2023 | 3669 | 0.090 |
Why?
|
| History, 20th Century | 1 | 2013 | 544 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 885 | 0.090 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2011 | 46 | 0.090 |
Why?
|
| Pandemics | 1 | 2020 | 1610 | 0.090 |
Why?
|
| Electronic Mail | 1 | 2011 | 51 | 0.090 |
Why?
|
| Thoracic Diseases | 1 | 2010 | 30 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 254 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 1340 | 0.090 |
Why?
|
| Tumor Burden | 3 | 2023 | 2033 | 0.090 |
Why?
|
| Computer Simulation | 1 | 2016 | 1570 | 0.090 |
Why?
|
| Aftercare | 2 | 2022 | 252 | 0.090 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2017 | 641 | 0.090 |
Why?
|
| Odds Ratio | 4 | 2021 | 2311 | 0.090 |
Why?
|
| Motivation | 1 | 2013 | 516 | 0.090 |
Why?
|
| Cost of Illness | 2 | 2023 | 505 | 0.090 |
Why?
|
| Up-Regulation | 2 | 1995 | 2422 | 0.090 |
Why?
|
| Quaternary Ammonium Compounds | 3 | 2006 | 67 | 0.080 |
Why?
|
| Child | 10 | 2018 | 30559 | 0.080 |
Why?
|
| Genetic Variation | 2 | 2015 | 2166 | 0.080 |
Why?
|
| Statistics, Nonparametric | 4 | 2018 | 984 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 3345 | 0.080 |
Why?
|
| Marital Status | 1 | 2009 | 92 | 0.080 |
Why?
|
| Clone Cells | 2 | 2021 | 591 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 1993 | 1094 | 0.080 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 371 | 0.080 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 1060 | 0.080 |
Why?
|
| Students, Medical | 1 | 2014 | 423 | 0.080 |
Why?
|
| Bronchial Neoplasms | 1 | 2009 | 82 | 0.080 |
Why?
|
| Accreditation | 1 | 2009 | 137 | 0.080 |
Why?
|
| Hyperplasia | 2 | 2021 | 564 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 2359 | 0.080 |
Why?
|
| Recurrence | 4 | 2023 | 4878 | 0.080 |
Why?
|
| Aorta | 1 | 2012 | 670 | 0.080 |
Why?
|
| Overweight | 1 | 2011 | 484 | 0.080 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 7381 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2008 | 142 | 0.080 |
Why?
|
| Thoracic Vertebrae | 2 | 2009 | 200 | 0.080 |
Why?
|
| Factor Analysis, Statistical | 1 | 2009 | 353 | 0.080 |
Why?
|
| Contrast Media | 1 | 2005 | 1499 | 0.080 |
Why?
|
| Drug Administration Schedule | 4 | 2019 | 3530 | 0.080 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2008 | 76 | 0.080 |
Why?
|
| Age Factors | 6 | 2020 | 5457 | 0.080 |
Why?
|
| Animals | 17 | 2022 | 61956 | 0.070 |
Why?
|
| Canada | 1 | 2009 | 440 | 0.070 |
Why?
|
| Chromosome Aberrations | 2 | 2021 | 2035 | 0.070 |
Why?
|
| Antigens, Nuclear | 1 | 2008 | 126 | 0.070 |
Why?
|
| Physicians, Women | 1 | 2009 | 103 | 0.070 |
Why?
|
| Replantation | 1 | 2008 | 60 | 0.070 |
Why?
|
| Premedication | 2 | 2005 | 133 | 0.070 |
Why?
|
| Adenofibroma | 1 | 2007 | 20 | 0.070 |
Why?
|
| Surgical Stapling | 1 | 2007 | 35 | 0.070 |
Why?
|
| Sarcoma, Ewing | 2 | 2016 | 428 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2018 | 4644 | 0.070 |
Why?
|
| Sleep Wake Disorders | 1 | 2011 | 372 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 3949 | 0.070 |
Why?
|
| Mastectomy | 1 | 2013 | 1553 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2012 | 5002 | 0.070 |
Why?
|
| Interleukin-10 | 2 | 2004 | 483 | 0.070 |
Why?
|
| Hemostatics | 1 | 2007 | 82 | 0.070 |
Why?
|
| Esophageal Stenosis | 1 | 2007 | 91 | 0.070 |
Why?
|
| Carcinoid Tumor | 1 | 2009 | 282 | 0.070 |
Why?
|
| Pneumonia, Aspiration | 1 | 2006 | 45 | 0.070 |
Why?
|
| Data Collection | 1 | 2009 | 608 | 0.070 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2004 | 75 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2008 | 413 | 0.070 |
Why?
|
| Preoperative Period | 2 | 2013 | 346 | 0.070 |
Why?
|
| Mouthwashes | 1 | 2006 | 42 | 0.070 |
Why?
|
| Ultrasonography, Interventional | 1 | 2009 | 424 | 0.070 |
Why?
|
| Cardiovascular Diseases | 3 | 2016 | 2224 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2008 | 2313 | 0.070 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2009 | 689 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 1580 | 0.060 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2023 | 437 | 0.060 |
Why?
|
| Radiation Injuries | 2 | 2003 | 1471 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2009 | 647 | 0.060 |
Why?
|
| Biopsy | 4 | 2020 | 3484 | 0.060 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2006 | 111 | 0.060 |
Why?
|
| Immunotherapy | 3 | 2024 | 3557 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 681 | 0.060 |
Why?
|
| Suture Techniques | 1 | 2007 | 292 | 0.060 |
Why?
|
| Ovarian Neoplasms | 2 | 2016 | 4795 | 0.060 |
Why?
|
| Transgenes | 2 | 2004 | 576 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2023 | 2345 | 0.060 |
Why?
|
| Family | 1 | 2009 | 783 | 0.060 |
Why?
|
| Heterografts | 2 | 2019 | 738 | 0.060 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2005 | 127 | 0.060 |
Why?
|
| Liposomes | 2 | 2004 | 704 | 0.060 |
Why?
|
| Linear Models | 2 | 2018 | 1093 | 0.060 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2005 | 84 | 0.060 |
Why?
|
| Injections, Intravenous | 4 | 2005 | 591 | 0.060 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 1034 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 4372 | 0.060 |
Why?
|
| Chyle | 1 | 2024 | 22 | 0.060 |
Why?
|
| DNA Copy Number Variations | 2 | 2021 | 1568 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2011 | 927 | 0.060 |
Why?
|
| Pain Measurement | 2 | 2020 | 1016 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2008 | 1049 | 0.060 |
Why?
|
| B-Lymphocytes | 2 | 2020 | 1424 | 0.060 |
Why?
|
| Multimodal Imaging | 2 | 2021 | 550 | 0.060 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2004 | 136 | 0.060 |
Why?
|
| Kallikreins | 1 | 2004 | 86 | 0.060 |
Why?
|
| Comorbidity | 4 | 2015 | 2394 | 0.060 |
Why?
|
| ROC Curve | 3 | 2012 | 1248 | 0.060 |
Why?
|
| Radiography | 2 | 2010 | 1986 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2018 | 17061 | 0.050 |
Why?
|
| Cholesterol | 2 | 2004 | 659 | 0.050 |
Why?
|
| Longitudinal Studies | 3 | 2016 | 2057 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 1235 | 0.050 |
Why?
|
| Cell Survival | 3 | 2019 | 3063 | 0.050 |
Why?
|
| Mice | 8 | 2022 | 35600 | 0.050 |
Why?
|
| Deglutition Disorders | 1 | 2007 | 489 | 0.050 |
Why?
|
| Bias | 1 | 2023 | 216 | 0.050 |
Why?
|
| Forced Expiratory Volume | 1 | 2024 | 327 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 1174 | 0.050 |
Why?
|
| Cytokines | 3 | 2020 | 2825 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2003 | 275 | 0.050 |
Why?
|
| Blood Loss, Surgical | 1 | 2004 | 295 | 0.050 |
Why?
|
| Income | 1 | 2023 | 235 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2018 | 2457 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 550 | 0.050 |
Why?
|
| Heart Arrest, Induced | 1 | 2002 | 85 | 0.050 |
Why?
|
| Bronchoalveolar Lavage Fluid | 4 | 1995 | 269 | 0.050 |
Why?
|
| Aniline Compounds | 1 | 2023 | 206 | 0.050 |
Why?
|
| Radiotherapy Dosage | 6 | 2007 | 4019 | 0.050 |
Why?
|
| Matched-Pair Analysis | 1 | 2021 | 100 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 16215 | 0.050 |
Why?
|
| Integrins | 2 | 1993 | 275 | 0.050 |
Why?
|
| Lymphoma | 1 | 2010 | 1519 | 0.050 |
Why?
|
| Hormone Replacement Therapy | 1 | 2004 | 214 | 0.050 |
Why?
|
| Radiation Pneumonitis | 2 | 2018 | 313 | 0.050 |
Why?
|
| Organoplatinum Compounds | 2 | 2014 | 704 | 0.050 |
Why?
|
| Rats | 6 | 1995 | 6441 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 328 | 0.050 |
Why?
|
| Bayes Theorem | 2 | 2018 | 1060 | 0.050 |
Why?
|
| Intercostal Nerves | 1 | 2020 | 31 | 0.050 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 5162 | 0.050 |
Why?
|
| Meningioma | 1 | 2004 | 308 | 0.050 |
Why?
|
| Genotype | 3 | 2015 | 4252 | 0.050 |
Why?
|
| Educational Personnel | 1 | 2020 | 3 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 275 | 0.050 |
Why?
|
| Immunohistochemistry | 5 | 2021 | 7655 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 3917 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 450 | 0.050 |
Why?
|
| Genomics | 2 | 2024 | 2835 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 2011 | 4821 | 0.040 |
Why?
|
| Neck | 1 | 2022 | 395 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2021 | 219 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 1903 | 0.040 |
Why?
|
| Vinblastine | 1 | 2001 | 462 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2021 | 232 | 0.040 |
Why?
|
| Thymectomy | 1 | 2020 | 80 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2021 | 220 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2021 | 229 | 0.040 |
Why?
|
| Reference Values | 2 | 2018 | 1133 | 0.040 |
Why?
|
| Thyroidectomy | 1 | 2022 | 489 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2022 | 5149 | 0.040 |
Why?
|
| Registries | 2 | 2018 | 2211 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 484 | 0.040 |
Why?
|
| Transplantation, Autologous | 3 | 2012 | 2067 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2022 | 1075 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 1557 | 0.040 |
Why?
|
| Metaplasia | 1 | 2021 | 384 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2008 | 2115 | 0.040 |
Why?
|
| Meningeal Neoplasms | 1 | 2004 | 473 | 0.040 |
Why?
|
| Interleukin-4 | 2 | 2005 | 290 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2019 | 115 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2021 | 518 | 0.040 |
Why?
|
| Tumor Escape | 1 | 2021 | 247 | 0.040 |
Why?
|
| Postoperative Period | 2 | 2016 | 666 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2021 | 338 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 311 | 0.040 |
Why?
|
| Random Allocation | 2 | 2019 | 741 | 0.040 |
Why?
|
| Anesthetics, Local | 1 | 2020 | 178 | 0.040 |
Why?
|
| Oncogenes | 1 | 2022 | 699 | 0.040 |
Why?
|
| Lymph Node Excision | 2 | 2018 | 2062 | 0.040 |
Why?
|
| Antigens, CD20 | 1 | 2019 | 207 | 0.040 |
Why?
|
| Adenosine | 1 | 2020 | 294 | 0.040 |
Why?
|
| Infant | 2 | 2018 | 13999 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2021 | 483 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2023 | 787 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 485 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 380 | 0.040 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2018 | 29 | 0.040 |
Why?
|
| Quebec | 1 | 2018 | 20 | 0.040 |
Why?
|
| Nerve Block | 1 | 2020 | 184 | 0.040 |
Why?
|
| Protein Folding | 1 | 2019 | 297 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 525 | 0.040 |
Why?
|
| RNA, Messenger | 4 | 2018 | 6390 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2003 | 1140 | 0.040 |
Why?
|
| Methylene Blue | 1 | 2018 | 53 | 0.040 |
Why?
|
| Cetuximab | 1 | 2020 | 474 | 0.040 |
Why?
|
| Inflammation | 2 | 2005 | 2518 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2020 | 374 | 0.040 |
Why?
|
| Costs and Cost Analysis | 2 | 2010 | 310 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 255 | 0.040 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2000 | 159 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1824 | 0.040 |
Why?
|
| Debridement | 1 | 2018 | 121 | 0.040 |
Why?
|
| Surgical Instruments | 1 | 2018 | 141 | 0.040 |
Why?
|
| Radiography, Interventional | 1 | 2020 | 311 | 0.040 |
Why?
|
| Nomograms | 1 | 2020 | 312 | 0.040 |
Why?
|
| Deoxycytidine | 2 | 2014 | 1389 | 0.040 |
Why?
|
| Immune Complex Diseases | 2 | 1995 | 12 | 0.040 |
Why?
|
| Phagocytosis | 2 | 2003 | 292 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2018 | 116 | 0.040 |
Why?
|
| Dialysis | 1 | 2017 | 25 | 0.040 |
Why?
|
| Risk | 1 | 2002 | 1939 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2022 | 961 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 4831 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2020 | 336 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2003 | 1497 | 0.040 |
Why?
|
| Glycolysis | 1 | 2020 | 530 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2020 | 639 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 896 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 1586 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2021 | 699 | 0.030 |
Why?
|
| Exosomes | 1 | 2019 | 255 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 1710 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 714 | 0.030 |
Why?
|
| Vocational Guidance | 1 | 2016 | 2 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2018 | 749 | 0.030 |
Why?
|
| Burnout, Professional | 1 | 2020 | 224 | 0.030 |
Why?
|
| Biomarkers | 2 | 2022 | 5051 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2021 | 1726 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2017 | 322 | 0.030 |
Why?
|
| Ribs | 1 | 2016 | 82 | 0.030 |
Why?
|
| Consumer Behavior | 1 | 2016 | 44 | 0.030 |
Why?
|
| Vascular Surgical Procedures | 1 | 2021 | 619 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2021 | 12103 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2019 | 757 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 1020 | 0.030 |
Why?
|
| Instillation, Drug | 1 | 1995 | 15 | 0.030 |
Why?
|
| Contraindications | 1 | 2006 | 154 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2016 | 149 | 0.030 |
Why?
|
| Glucose | 1 | 2021 | 1218 | 0.030 |
Why?
|
| Immunoglobulin A | 2 | 1993 | 271 | 0.030 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1995 | 106 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2006 | 291 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2009 | 8699 | 0.030 |
Why?
|
| Receptors, Leukocyte-Adhesion | 1 | 1995 | 17 | 0.030 |
Why?
|
| Etoposide | 2 | 2012 | 907 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 1049 | 0.030 |
Why?
|
| Kidney | 1 | 2004 | 2121 | 0.030 |
Why?
|
| Sarcoma, Synovial | 1 | 2016 | 141 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 2650 | 0.030 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 1995 | 15 | 0.030 |
Why?
|
| Scoliosis | 1 | 2016 | 145 | 0.030 |
Why?
|
| Oxygenases | 1 | 2014 | 26 | 0.030 |
Why?
|
| Software | 1 | 2022 | 1355 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2015 | 121 | 0.030 |
Why?
|
| Peroxidase | 1 | 1995 | 133 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2011 | 6224 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 1723 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2018 | 481 | 0.030 |
Why?
|
| Immunoglobulin G | 3 | 1993 | 1129 | 0.030 |
Why?
|
| Complement C5a | 1 | 1994 | 35 | 0.030 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1994 | 64 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 1246 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2021 | 1875 | 0.030 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2014 | 35 | 0.030 |
Why?
|
| Receptors, Complement | 1 | 1994 | 48 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 1291 | 0.030 |
Why?
|
| Protons | 1 | 2017 | 481 | 0.030 |
Why?
|
| Models, Cardiovascular | 1 | 2015 | 189 | 0.030 |
Why?
|
| Mentoring | 1 | 2016 | 105 | 0.030 |
Why?
|
| Pain | 1 | 2022 | 1694 | 0.030 |
Why?
|
| Microspheres | 1 | 2005 | 237 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 392 | 0.030 |
Why?
|
| Antigens, CD | 3 | 1993 | 1418 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 2357 | 0.030 |
Why?
|
| Peritoneal Cavity | 1 | 1993 | 58 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 1690 | 0.030 |
Why?
|
| Equipment Design | 1 | 2017 | 1197 | 0.030 |
Why?
|
| Antibodies | 2 | 1993 | 809 | 0.030 |
Why?
|
| Cytochalasin B | 1 | 1993 | 15 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 1993 | 168 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1993 | 160 | 0.030 |
Why?
|
| Pyridines | 1 | 2020 | 1313 | 0.030 |
Why?
|
| Video Recording | 1 | 2015 | 281 | 0.030 |
Why?
|
| Capecitabine | 1 | 2014 | 390 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 2016 | 342 | 0.030 |
Why?
|
| Endothelium | 1 | 1993 | 156 | 0.030 |
Why?
|
| Fluoresceins | 1 | 1993 | 74 | 0.030 |
Why?
|
| Mice, Inbred C3H | 2 | 2004 | 404 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1993 | 248 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 3 | 2022 | 4481 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2019 | 1933 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 1995 | 3028 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 1993 | 186 | 0.030 |
Why?
|
| Fluorescence | 1 | 1993 | 198 | 0.030 |
Why?
|
| Manometry | 1 | 2012 | 72 | 0.030 |
Why?
|
| Luciferases | 2 | 2004 | 460 | 0.030 |
Why?
|
| Pressure | 1 | 2012 | 178 | 0.030 |
Why?
|
| Hot Temperature | 1 | 1993 | 289 | 0.030 |
Why?
|
| Gastroscopy | 1 | 2012 | 156 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 5056 | 0.030 |
Why?
|
| Robotics | 1 | 2016 | 365 | 0.020 |
Why?
|
| Gastrointestinal Motility | 1 | 2012 | 85 | 0.020 |
Why?
|
| Cell Count | 1 | 1993 | 512 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2020 | 1207 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2023 | 3438 | 0.020 |
Why?
|
| Pulmonary Alveoli | 1 | 1993 | 220 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2020 | 1546 | 0.020 |
Why?
|
| Health Status | 1 | 2015 | 631 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 655 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 1993 | 1054 | 0.020 |
Why?
|
| Motor Activity | 1 | 2015 | 699 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2006 | 4147 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2004 | 2431 | 0.020 |
Why?
|
| Dumping Syndrome | 1 | 2010 | 7 | 0.020 |
Why?
|
| Elective Surgical Procedures | 1 | 2012 | 249 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 729 | 0.020 |
Why?
|
| Macrophages | 1 | 2017 | 1350 | 0.020 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 861 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 3658 | 0.020 |
Why?
|
| Macrophages, Alveolar | 2 | 2004 | 71 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2010 | 218 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2010 | 129 | 0.020 |
Why?
|
| Mediastinoscopy | 1 | 2009 | 33 | 0.020 |
Why?
|
| Program Development | 1 | 2011 | 259 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2399 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 5728 | 0.020 |
Why?
|
| Cognition | 1 | 2015 | 959 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2012 | 533 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2023 | 5438 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2009 | 111 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 325 | 0.020 |
Why?
|
| Quality of Life | 1 | 2023 | 4761 | 0.020 |
Why?
|
| Image Cytometry | 1 | 2008 | 44 | 0.020 |
Why?
|
| Ku Autoantigen | 1 | 2008 | 82 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 500 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 1994 | 5694 | 0.020 |
Why?
|
| Acute Disease | 1 | 1993 | 2493 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 4961 | 0.020 |
Why?
|
| Sputum | 1 | 2008 | 157 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 690 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2010 | 509 | 0.020 |
Why?
|
| Granulation Tissue | 1 | 1987 | 26 | 0.020 |
Why?
|
| Cytodiagnosis | 1 | 2008 | 201 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 1099 | 0.020 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 368 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2008 | 305 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2008 | 313 | 0.020 |
Why?
|
| Bronchi | 1 | 2008 | 325 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2004 | 1525 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 5408 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2006 | 159 | 0.020 |
Why?
|
| Drug Costs | 1 | 2007 | 140 | 0.020 |
Why?
|
| Cell Movement | 1 | 1993 | 2472 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 1987 | 268 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 147 | 0.020 |
Why?
|
| Klebsiella pneumoniae | 1 | 2006 | 101 | 0.020 |
Why?
|
| Candida albicans | 1 | 2006 | 186 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 2005 | 330 | 0.020 |
Why?
|
| Nausea | 1 | 2007 | 539 | 0.020 |
Why?
|
| Genetic Therapy | 2 | 2003 | 1716 | 0.020 |
Why?
|
| Life Tables | 1 | 2004 | 120 | 0.020 |
Why?
|
| Opportunistic Infections | 1 | 2006 | 234 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2006 | 497 | 0.010 |
Why?
|
| Biofilms | 1 | 2006 | 204 | 0.010 |
Why?
|
| Ethanol | 1 | 2006 | 272 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 1441 | 0.010 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2006 | 252 | 0.010 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 4958 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 14849 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2005 | 277 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2007 | 581 | 0.010 |
Why?
|
| Umbilical Veins | 2 | 1994 | 118 | 0.010 |
Why?
|
| Abdomen | 1 | 2005 | 347 | 0.010 |
Why?
|
| Awards and Prizes | 1 | 2005 | 86 | 0.010 |
Why?
|
| Age of Onset | 1 | 2006 | 853 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 886 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 497 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 2004 | 143 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2004 | 334 | 0.010 |
Why?
|
| Menopause | 1 | 2004 | 160 | 0.010 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2005 | 275 | 0.010 |
Why?
|
| Isotretinoin | 1 | 2003 | 160 | 0.010 |
Why?
|
| Pinocytosis | 1 | 2003 | 28 | 0.010 |
Why?
|
| Transfusion Reaction | 1 | 2003 | 101 | 0.010 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2008 | 450 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2008 | 847 | 0.010 |
Why?
|
| Immobilization | 1 | 2003 | 91 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 2003 | 168 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2006 | 1076 | 0.010 |
Why?
|
| Prevalence | 1 | 2010 | 3404 | 0.010 |
Why?
|
| Bleomycin | 1 | 2004 | 482 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 453 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 2006 | 562 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 727 | 0.010 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 310 | 0.010 |
Why?
|
| Rabbits | 2 | 1993 | 1028 | 0.010 |
Why?
|
| Plasmids | 1 | 2004 | 936 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 1379 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2004 | 631 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 1189 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2005 | 1050 | 0.010 |
Why?
|
| Karnofsky Performance Status | 1 | 2000 | 174 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 742 | 0.010 |
Why?
|
| Thoracostomy | 1 | 2000 | 47 | 0.010 |
Why?
|
| Hospital Charges | 1 | 2000 | 87 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2003 | 804 | 0.010 |
Why?
|
| Obesity | 1 | 2011 | 2904 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 1987 | 1181 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 5776 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2001 | 1437 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2003 | 1042 | 0.010 |
Why?
|
| Disease Management | 1 | 2003 | 1090 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2008 | 4116 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 1857 | 0.010 |
Why?
|
| Drainage | 1 | 2000 | 462 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2000 | 383 | 0.010 |
Why?
|
| Brachytherapy | 1 | 2003 | 1005 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 2003 | 1330 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2005 | 848 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2004 | 4329 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 3597 | 0.010 |
Why?
|
| Weight Loss | 1 | 2000 | 628 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 5759 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2003 | 1857 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2005 | 2651 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2000 | 591 | 0.010 |
Why?
|
| Models, Biological | 1 | 2004 | 3194 | 0.010 |
Why?
|
| L-Selectin | 1 | 1995 | 36 | 0.010 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1995 | 73 | 0.010 |
Why?
|
| Receptor, Anaphylatoxin C5a | 1 | 1994 | 13 | 0.010 |
Why?
|
| Survivors | 1 | 2000 | 1021 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1995 | 329 | 0.010 |
Why?
|
| Histamine | 1 | 1994 | 58 | 0.010 |
Why?
|
| P-Selectin | 1 | 1994 | 110 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 204 | 0.010 |
Why?
|
| CD11 Antigens | 1 | 1993 | 23 | 0.010 |
Why?
|
| Palliative Care | 1 | 2005 | 2178 | 0.010 |
Why?
|
| CD18 Antigens | 1 | 1993 | 86 | 0.010 |
Why?
|
| E-Selectin | 1 | 1993 | 106 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 1994 | 246 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1993 | 707 | 0.010 |
Why?
|
| Integrin beta1 | 1 | 1993 | 128 | 0.010 |
Why?
|
| Kinetics | 1 | 1994 | 2220 | 0.010 |
Why?
|
| Intubation, Intratracheal | 1 | 1995 | 469 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 1995 | 1005 | 0.010 |
Why?
|
| Apoptosis | 1 | 2003 | 7757 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1994 | 3476 | 0.000 |
Why?
|
| Hydroxyproline | 1 | 1987 | 9 | 0.000 |
Why?
|
| Serum Albumin, Bovine | 1 | 1987 | 84 | 0.000 |
Why?
|
| Gene Expression | 1 | 1994 | 3640 | 0.000 |
Why?
|
| Dogs | 1 | 1987 | 1160 | 0.000 |
Why?
|
| Cicatrix | 1 | 1987 | 187 | 0.000 |
Why?
|
| Echocardiography | 1 | 1987 | 1228 | 0.000 |
Why?
|